Pharmacovigilance – News and Features

Zora will provide laboratory services to pharmaceutical industry in the area of metabolomics and associated bioinformatics.

Inovio’s Phase I/II study of patients with recurrent breast cancer showed safety, tolerability and achieved a 75% complete tumor response rate.

The genes discovered are important potential targets for drugs that could selectively cut off a tumor's blood supply without affecting the blood vessels.

Duke researchers have opened up a new way to screen drugs for possible heart-related side effects and to develop new drugs.

A study demonstrating therapeutic utilization of human stem cells, including application to X-SCID was presented at the 10th ASGT meeting.

The data from a Phase I clinical study of anti-cancer drug candidate has been published in the 2007 American Society for Clinical Oncology Proceedings.

Agreement will improve R&D productivity by augmenting life sciences content available via MDL® Isentris ® system and enabling distribution of Aureus databases in MDL® Direct format.

The Phase I clinical trial is designed to assess the safety, tolerability and pharmacokinetics of an investigational cancer compound.

University of California researchers demonstrate how they have created nanotubes that can hold therapeutic drugs and deliver in a highly-controlled manner.

Lectus receives the award based on the significant achievements and progress made by the company.